Format

Send to

Choose Destination
J Surg Oncol. 2013 Jan;107(1):15-22. doi: 10.1002/jso.23192. Epub 2012 Jun 21.

Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer.

Author information

1
Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. jordan.winter@jefferson.edu

Abstract

Serum CA 19-9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens.

PMID:
22729569
DOI:
10.1002/jso.23192
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center